Cargando…
Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
OBJECTIVES: Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response aft...
Autores principales: | Bitzenhofer, Michaela, Suter-Riniker, Franziska, Moor, Matthias B., Sidler, Daniel, Horn, Michael P., Gschwend, Anna, Staehelin, Cornelia, Rauch, Andri, Helbling, Arthur, Jörg, Lukas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182562/ https://www.ncbi.nlm.nih.gov/pubmed/35679232 http://dx.doi.org/10.1371/journal.pone.0268780 |
Ejemplares similares
-
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
por: Sidler, Daniel, et al.
Publicado: (2022) -
Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy
por: Gössi, Simona, et al.
Publicado: (2022) -
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply
por: Moor, Matthias B, et al.
Publicado: (2022) -
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
por: Moor, Matthias B, et al.
Publicado: (2021) -
Rituximab: Humoral immunodeficiency: case report
Publicado: (2021)